The decision to request BIS in asymptomatic patients with MBC would be influenced by tumor characteristics for 83 % of physicians not requesting BIS, mainly HER2 positivity (HER2+; 79 %) and in TNBC (63 %) (Supplementary Table 3). Here, ERBB2 is linked to neoplasm.